

Use of Long-Acting Injectable Antipsychotics



EPI GUIDE

The Canadian Consortium for Early Intervention in Psychosis (CCEIP) clinical guidance documents provide clinicians with evidence-based recommendations for the diagnosis, assessment, and management of psychosis. This guidance is developed by an expert panel of clinicians who evaluate the available literature and develop consensus-based recommendations.

DO

- Offer long-acting injectable antipsychotic medication (LAIs) often, at **all phases of illness**, particularly in the **first episode**, as they are considered best practice.^{1,2}
- Use **shared decision making** to discuss therapeutic options, including LAIs, in a collaborative environment.¹⁻⁴
- Be **well-informed** in the current research and use of LAIs.¹
- **Focus on recovery** with the objective to improve patient's quality of life.¹

STOP

- Don't **wait to offer** LAIs.¹⁻³
- Don't only focus on **symptoms**.¹
- Don't assume patients will **reject LAIs** or want to avoid needles, be aware of your own bias.^{1,3}

CONSIDER

- Consider LAIs in case of apparent or potential **partial/nonadherence** to oral antipsychotic therapy.¹⁻³
- **Proactively address situations** that may lead to a change in therapy, such as pregnancy, travel, or transfer of care.¹⁻³

LAIs are a valuable tool for treating schizophrenia spectrum disorders (SSDs)

When considering therapeutic options for people with SSDs, LAIs are associated with significantly lower relapse and treatment discontinuation rates than oral antipsychotic therapy (APs), as well as more frequent remission.¹⁻⁸

Benefits of LAIs¹⁻¹¹

- Offers more reliable and sustained therapy, leading to reduced relapses and decreased rates of rehospitalization/emergency admissions.
- Improves functional outcomes and contributes to a better quality of life.
- Facilitates engagement in psychosocial interventions.
- Offers a valid measure of medication adherence.
- Provides more convenience, longer dosing intervals, and not having to remember (or be reminded of) daily APs.
- Decreases some side effects, such as sedation, compared to oral APs.
- May contribute to reduce the risk of all-cause and non-suicidal mortality risk, especially in early phase.

Offering LAIs

LAIs should be offered during all phases of SSD, including the first episode, and those under community treatment or court orders.¹⁻³ Educating patients and families on the benefits of LAIs may help them choose the best treatment option and achieve optimal clinical outcomes.^{3,6} The *Offering Patients Therapeutic Information on Medication Alternatives (OPTIMA) tool* can be used to guide discussions about the option of LAIs with patients. It includes an educational protocol, patient decision aid, and questionnaire.



Patient and family education on LAIs^{2-3, 14-15}

Information should include:

- Effectiveness
- Administration
- Frequency of injections
- Cost

Strategies for joint decision making centered on patient preferences



Motivational
interviewing



Shared decision
making



Improvements^{2-3, 14-15}

- Insight
- Adherence
- Knowledge
- Participation
- Acceptance
- Satisfaction

LAI practice guidelines: Adapted QAAPAPLE (Québec) ²

First episode or established psychosis

- Use family intervention, psychoeducation, motivational interviewing, and cognitive behavior therapy to optimize medication adherence and help build insight.
- Question polypharmacy (50%) and vulnerability of adverse reactions (e.g. extrapyramidal signs or neuroleptic malignant syndrome) and comorbid conditions (e.g. diabetes, multiple sclerosis, HIV).

Selecting antipsychotic therapy

- Propose LAI as first line therapy to all patients
- Engage in shared decision making using the OPTIMA tool
- Consider potential for nonadherence

Adherent to therapy

Offer LAI, otherwise orals

Offer LAI to patients with nonadherence, or profile at risk of nonadherence

e.g. Inconsistent use, lack of insight, lack of support, in situations that may lead to a change or interruption in therapy

If nonresponsive to therapy

Ensure adherence to confirm nonresponsiveness

Accepts LAI

Revisit therapeutic options as needed

Refuses LAI but accepts help to optimize oral adherence

Consider electronic/pill box, fast dissolving/liquid oral medication administered with third-party supervision

Categorical refusal of therapy

Consider mandatory treatment

Short interval LAI (Q2-4W)

For patients who are unstable, or require more frequent monitoring and contact with care team*

Long interval LAI (Q>2M)

For patients who are more stable, live far away from clinic, or are unable to attend clinic hours*

If nonresponsive after adherence confirmed through direct supervision by care team

Consider clozapine after ≥2 different antipsychotics, ideally >1 LAI

Consider assessment of antipsychotic plasma levels

If adequate dosage and non/inadequate response confirmed

If subtherapeutic antipsychotic plasma levels, adjust therapy or offer LAI

*Consider reducing interval if relapse is occurring before retreatment

Unstable or nonresponsive = LAI

Stable = Maintain oral

Adapted from Stip E, Grignon S, Roy MA, et al. From QAAPAPLE 1 to QAAPAPLE 2: how do we move from one algorithm to another one with Long Acting Antipsychotics (LAIs). *Expert Review of Neurotherapeutics*. 2020;20(12):1325-1332. doi:10.1080/14737175.2020.1826930

Managing breakthrough symptoms

- Clinicians should periodically review medication options, regardless of perceived adherence.^{1,2}
- If symptoms of SSD begin to appear while on LAIs, clinicians should evaluate the patient for potential illness or comorbidities, substance use, or missed doses. Addressing patient stressors, optimizing nonpharmacological therapies, or increasing monitoring may improve symptoms.¹¹
- If symptoms continue, consider ensuring proper LAI administration, increasing LAI dose, decreasing dosing intervals, supplementing with oral APs, or switching LAIs.¹¹
- Clinicians should anticipate situations that may lead to a change or interruption in therapy, such as pregnancy, travel, moving, drug coverage, or changes in care teams.^{1,2}

References

1. Malla A, Tibbo P, Chue P, et al. Long-Acting Injectable Antipsychotics: Recommendations for Clinicians. *Can J Psychiatry*. 2013;58(5 suppl):30-35. doi:10.1177/08874034130580505
2. Stip E, Grignon S, Roy MA, et al. From QAAPAPLE 1 to QAAPAPLE 2: how do we move from one algorithm to another one with Long Acting Antipsychotics (LAIs). *Expert Rev Neurother*. 2020;20(12):1325-1332. doi:10.1080/14737175.2020.1826930
3. Margolese H. OPTIMA Tool: Offering Patients Therapeutic Information on Medication Alternatives. Canadian Consortium for Early Intervention in Psychosis. Published November 2015. Accessed May 13, 2024. <https://www.epicanada.org/optima>
4. Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. *Can J Psychiatry*. 2017;62(9):604-616. doi:10.1177/0706743717720448
5. Brasso C, Bellino S, Bozzatello P, et al. Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient's Subjective Quality of Life, Well-Being, and Satisfaction. *J Clin Med*. 2023;12(22):6985. doi:10.3390/jcm12226985
6. Lian L, Kim DD, Procyshyn RM, Cázares D, Honer WG, Barr AM. Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. *PLOS ONE*. 2022;17(4):e0267808. doi:10.1371/journal.pone.0267808
7. Taylor M, Ng KYB. Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. *Aust N Z J Psychiatry*. Published online December 3, 2012. doi:10.1177/0004867412470010
8. Haddad PM, Correll CU. Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. *Expert Opin Pharmacother*. Published online March 4, 2023. Accessed June 18, 2024. www.tandfonline.com/doi/abs/10.1080/14656566.2023.2181073
9. Lin D, Thompson-Leduc P, Gheeler I, et al. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. *CNS Drugs*. 2021;35(5):469-481. doi:10.1007/s40263-021-00815-y
10. McKee KA, Crocker CE, Tibbo PG. Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study. *BMC Psychiatry*. 2021;21(1):633. doi:10.1186/s12888-021-03646-9
11. Correll CU, Sliva JK, Najarian DM, Saklad SR. Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. *CNS Spectr*. 2019;24(4):354-370. doi:10.1017/S1092852918001098
12. Keepers GA, Fochtmann LJ, Anzai JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia - Executive Summary. *Am J Psychiatry*. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901
13. Højlund M, Correll CU. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. *Expert Opin Pharmacother*. 2023;24(13):1463-1489. doi:10.1080/14656566.2023.2228686
14. Chien WT, Mui JH, Cheung EF, Gray R. Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial. *Trials*. 2015;16(1):270. doi:10.1186/s13063-015-0785-z
15. Fiorillo A, Barlati S, Bellomo A, et al. The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review. *Ann Gen Psychiatry*. 2020;19(1):43. doi:10.1186/s12991-020-00293-4

The Canadian Consortium for Early Intervention in Psychosis (CCEIP) clinical guidance documents are not clinical practice guidelines; they are the CCEIP's best recommendations based on current knowledge, and no warranty or guaranty is expressed or implied. The content provided is for informational purposes for medical professionals only and is not intended to be used or relied upon by them as specific medical advice, diagnosis, or treatment, the determination of which remains the responsibility of the medical professionals for their patients.

Authors: Phil Tibbo, MD FRPC (chair); Howard Margolese, MD, MSc, FRPC; Marc-André Roy, MD, MSc, FRPC



EPI CANADA
Early Psychosis Intervention